Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-007: pembrolizumab with or without lenvatinib for previously untreated metastatic non-small cell lung cancer with PD-L1 TPS at least 1%
MOH_2019-02-11_004894Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + lenvatinib with Pembrolizumab + placebo (2 arms). Started Jan 2019; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-02-11_004894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-11_004894.